Journal
MOLECULAR THERAPY
Volume 2, Issue 3, Pages 218-222Publisher
CELL PRESS
DOI: 10.1006/mthe.2000.0116
Keywords
lentivirus vector; retroviral vector; complement; resistance; human sera inactivation; VSV G pseudotyping
Ask authors/readers for more resources
Lentiviral vectors transduce dividing and postmitotic cells and thus are being developed toward therapies for many diseases affecting diverse tissues. One essential requirement for efficacy will be that vector particles are resistant to inactivation by human serum complement. Most animal studies with lentiviral vectors have utilized VSV-G pseudotyped envelopes. Here we demonstrate that VSV-G pseudotyped HIV and FIV vectors produced in human cells are inactivated by human serum complement, suggesting that alternative envelopes may be required for therapeutic efficacy for many clinical applications of lentiviral vectors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available